Nektar Therapeutics (BMV:NKTR)

Mexico flag Mexico · Delayed Price · Currency is MXN
414.00
0.00 (0.00%)
At close: Aug 7, 2025
-46.00%
Market Cap 9.69B
Revenue (ttm) 1.41B
Net Income (ttm) -2.31B
Shares Out n/a
EPS (ttm) -164.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8
Average Volume 110
Open 414.00
Previous Close 414.00
Day's Range 414.00 - 414.00
52-Week Range 165.00 - 414.00
Beta n/a
RSI 34.19
Earnings Date Aug 6, 2025

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro... [Read more]

Industry Pharmaceutical Preparations
Founded 1990
Employees 61
Stock Exchange Mexican Stock Exchange
Ticker Symbol NKTR
Full Company Profile

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.